CP2289, a new 5-HT1 receptor ligand: Antagonistic activities on gastroenteric motility

Biological and Pharmaceutical Bulletin

Volumn 20, Issue 7, 1997, Pages 752-755

  Sato, Yasuo ^a   Imai, Megumi ^a   Amano, Kazuko ^a   Iwamatsu, Katsuyoshi ^a   Konno, Fukio ^a   Kurata, Yasushi ^a   Sakakibara, Shiro ^a   Hachisu, Mitsugu ^a   Izumi, Masaaki ^a   Matsuki, Norio ^b   Saito, Hiroshi ^b  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ATROPINE; CP 2289; GR 656630; GRANISETRON; KETANSERIN; MORPHINE; NICOTINE; PRAZOSIN; RAUWOLSCINE; SEROTONIN; SEROTONIN 3 RECEPTOR; SEROTONIN AGONIST; SPIPERONE; TETRODOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIEMETIC ACTIVITY; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GUINEA PIG; INSECTIVORE; INTESTINE MOTILITY; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; STOMACH EMPTYING; VOMITING;

EID: 0030739923     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.20.752     Document Type: Article

References (23)

1. For review, see: a) Kilpatrick G. J., Bunce K. T., Med. Res. Rev., 10, 441-475 (1990);
2. b) King F. D., Sanger G. J., Drugs of the Future. 14, 875-889 (1989).
3. a) Andrews P. L. R., Blower P. R., J. Pharm. Med., 13, 153-191 (1995);
4. b) Kato M., Ito K., Nishino S., Yamakuni H., Takasugi H., Chem. Pharm. Bull., 42, 2546-2555 (1994).
5. a) Sanger G. J., Nelson G. R., Eur. J. Pharmacol. 159, 113-124 (1989);
6. b) Bulter A., Hill J. M., Ireland S. J., Jordan C. C., Myers M. B., Br. J. Pharmacol., 94, 387-412 (1988):
7. c) Richardson B. P., Engel G., Donatsch P., Stadler P. A., Nature (London), 316, 126-131 (1985).
8. a) Ohta M., Suzuki T., Koide T., Matsuhisa A., Furuya T., Miyata K., Yanagisawa I., Chem. Pharm. Bull., 44, 991-999 (1996);
9. b) Greenshaw A. J., Trends Pharmacol. Sci., 14, 265-270 (1993):
10. c) Inoue M., Jpn. J. Clin. Med., 50, 517-529 (1992).
11. a) Miggins G. A., Joharchi N., Sellers E. M., J. Pharmacol. Exp. Ther., 264, 1440-1449 (1993);
12. b) Clark R. D., Muchowski J. M., Weinhardt K. K., Dillon M. P., Bioorganic. Med. Chem. Lett., 5, 1853-1856 (1995);
13. c) Bermudez J., Boyland P., King F. D., Summersell R. J., ibid., 3, 205-208 (1993):
14. d) Rault S., Lancelot J. C., Prunier H., Robba M., Renard P., Delagrange P., Pfeifler B., Caignard D. H., Guardiola-Lemaitre B., Hammon M., J. Med. Chem., 39, 2068-2080 (1996).
15. Kilpatrick G. J., Jones B. J., Tyers M. B., Nature (London), 330, 746-748 (1987).
16. Fozard J. R., Host M., Brit. J. Pharmacol., 77, 520P (1982)
17. Sanger G. J., Br. J. Pharmacol., 91, 77-87 (1987).
18. a) Mutoh M., Imanishi H., Torii Y., Tamura M., Saito H., Matsuki, N., Jpn. J. Pharmacol., 58, 321-324 (1992):
19. b) Torii Y., Saito H., Matsuki N., ibid., 55, 107-113 (1991);
20. c) Matsuki N., Ueno S., Kaji T., Ishihara A., Wang C-H., Saito H., ibid., 48, 303-306 (1988).
21. Monge A., Del Calmen Pena M., Palop J. A., Caldero J. M., Roca J., Garcia E., Romero G., Del Rio J., Lasheras B., J. Med. Chem., 37, 1320-1325 (1994).
22. a) Gyermek L., J. Clin. Pharmacol., 35, 845-855 (1995);
23. b) Yoshioka M., Saito H., Protein Nucleic Acid and Enzyme, 40, 700-708 (1995).